EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 31 / No 2 (Février 2015) Med Sci (Paris), 31 2 (2015) 197-202 References
Chémobiologie
Free Access
Issue
Med Sci (Paris)
Volume 31, Number 2, Février 2015
Chémobiologie
Page(s) 197 - 202
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20153102017
Published online 04 March 2015
  1. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996 ; 274 : 1531–1534. [CrossRef] [PubMed] [Google Scholar]
  2. Kuo LC. Fragment-based drug design : tools, practical approches and examples. Methods in enzymology, vol. 493. London : Academic Press, 2011 : 592 p. [Google Scholar]
  3. Congreve M, Carr R, Murray C, Jhoti H. A rule of three for fragment-based lead discovery? Drug Discov Today 2003 ; 8 : 876–877. [CrossRef] [Google Scholar]
  4. Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov Today 2004 ; 9 : 430–431. [CrossRef] [PubMed] [Google Scholar]
  5. Wells JA, Mcclendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007 ; 450 : 1001–1009. [CrossRef] [PubMed] [Google Scholar]
  6. Erlanson DA. Introduction to fragment-based drug discovery. Top Curr Chem 2012 ; 317 : 1–32. [CrossRef] [PubMed] [Google Scholar]
  7. Zartler ED, Shapiro MJ. Fragment-based drug discovery: a practical approach. New York : John Wiley and Sons Ltd, 2008 : 286 p. [Google Scholar]
  8. Dalvit C. NMR methods in fragment screening: theory and a comparison with other biophysical techniques. Drug Discov Today 2009 ; 14 : 1051–1057. [CrossRef] [PubMed] [Google Scholar]
  9. Cala O, Guilliere F, Krimm I. NMR-based analysis of protein-ligand interactions. Anal Bioanal Chem 2014 ; 406 : 943–956. [CrossRef] [PubMed] [Google Scholar]
  10. Davies DR. Screening ligands by X-ray crystallography. Methods Mol Biol 2014 ; 1140 : 315–323. [CrossRef] [PubMed] [Google Scholar]
  11. Navratilova I, Hopkins AL. Emerging role of surface plasmon resonance in fragment-based drug discovery. Future Med Chem 2011 ; 3 : 1809–1820. [CrossRef] [PubMed] [Google Scholar]
  12. Maple HJ, Garlish RA, Rigau-Roca L, et al. Automated protein-ligand interaction screening by mass spectrometry. J Med Chem 2012 ; 55 : 837–851. [CrossRef] [PubMed] [Google Scholar]
  13. Meiby E, Simmonite H, Le Strat L, et al. Fragment screening by weak affinity chromatography: comparison with established techniques for screening against HSP90. Anal Chem 2013 ; 85 : 6756–6766. [CrossRef] [PubMed] [Google Scholar]
  14. Silvestre HL, Blundell TL, Abell C, et al. Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery. Proc Natl Acad Sci USA 2013 ; 110 : 12984–12989. [CrossRef] [Google Scholar]
  15. Hajduk PJ, Huth JR, Tse C. Predicting protein druggability. Drug Discov Today 2005 ; 10 : 1675–1682. [CrossRef] [PubMed] [Google Scholar]
  16. Baker M.. Fragment-based lead discovery grows up. Nat Rev Drug Discov 2013 ; 12 : 5–7. [CrossRef] [PubMed] [Google Scholar]
  17. Scott DE, Coyne AG, Hudson SA, Abell C. Fragment-based approaches in drug discovery and chemical biology. Biochemistry 2012 ; 51 : 4990–5003. [CrossRef] [PubMed] [Google Scholar]
  18. Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008 ; 105 : 3041–3046. [CrossRef] [Google Scholar]
  19. Barelier S, Krimm I. Ligand specificity, privileged substructures and protein druggability from fragment-based screening. Curr Opin Chem Biol 2011 ; 15 : 469–474. [CrossRef] [PubMed] [Google Scholar]
  20. Barelier S, Pons J, Marcillat O, et al. Fragment-based deconstruction of Bcl-xL inhibitors. J Med Chem 2010 ; 53 : 2577–2588. [CrossRef] [PubMed] [Google Scholar]
  21. Barelier S, Pons J, Gehring K, et al. Ligand specificity in fragment-based drug design. J Med Chem 2010 ; 53 : 5256–5266. [CrossRef] [PubMed] [Google Scholar]
  22. Barelier S, Linard D, Pons J, et al. Discovery of fragment molecules that bind the human peroxiredoxin 5 active site. PLoS One 2010 ; 5 : e9744. [CrossRef] [PubMed] [Google Scholar]
  23. Krimm I, Lancelin JM, Praly JP. Binding evaluation of fragment-based scaffolds for probing allosteric enzymes. J Med Chem 2012 ; 55 : 1287–1295. [CrossRef] [PubMed] [Google Scholar]
  24. Krimm I. INPHARMA-based identification of ligand binding site in fragment-based drug design Med Chem Commun 2012 ; 3 : 605–610. [Google Scholar]
  25. Aguirre C, ten Brinck T, Walker O, et al. Bcl-xL conformational change upon fragment-binding revealed by NMR. PLoS One 2013 ; 8 : e64400. [CrossRef] [PubMed] [Google Scholar]
  26. Mullard A. Protein-protein interaction inhibitors get into the groove. Nat Rev Drug Discov 2012 ; 11 : 173–175. [CrossRef] [PubMed] [Google Scholar]
  27. Morley AD, Pugliese A, Birchall K, et al. Fragment-based hit identification: thinking in 3D. Drug Discov Today 2013 ; 23 : 1221–1227. [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.